<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592680</url>
  </required_header>
  <id_info>
    <org_study_id>MMS.2017.011</org_study_id>
    <nct_id>NCT03592680</nct_id>
  </id_info>
  <brief_title>Influence of Vitamin C on Post-operative Atrial Fibrillation</brief_title>
  <official_title>Influence of Oral Vitamine C Supplementation on the Incidence of Post-operative Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Algemeen Ziekenhuis Maria Middelares</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Algemeen Ziekenhuis Maria Middelares</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-operative atrial fibrillation (POAF) is the most common arrhythmia which typically
      develops 2-3 days after cardiac surgery. The incidence of POAF variates between 10% and 65%
      depending on the type of cardiac surgery and is especially high in patients which underwent
      Coronary Artery Bypass Grafting (CABG) and heart valve surgery. POAF is associated with
      increased morbidity and mortality and has a major impact on hospital resources.

      The precise pathogenesis of POAF is very complex, but several studies have demonstrated an
      association between inflammation, oxidative stress and POAF. Since this oxidative stress may
      be reduced by dietary anti-oxidantia such as vitamin C, the aim of this study is to evaluate
      the effect of oral vitamin C administration of the incidence of POAF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After obtaining informed consent, patients which are planned for CABG or heart valve surgery
      are randomly assigned into the Vitamin C group or Placebo Group.

      Each patient will receive 1 g Vitamin C or Placebo twice a day from 5 days before until 10
      days after surgery. The medication will be given orally and both patient and surgeon are
      blinded for the administrated medication.

      Patients receive standard of care in the post-operative period, which includes close
      monitoring for possible arrhythmias. If such an arrhythmia develops, this is treated
      according to the normal procedures. All information such as the used medication, the
      hospitalization / ICU length of stay and the ventilation time is automatically registered in
      the patient records.

      From each patient, three additional blood samples (peri-operative, post-operative Day 0,
      post-operative Day 1) will be obtained for analysis of Neutrophil gelatinase-associated
      lipocalin (NGAL), a possible marker of subclinical kidney damage. These samples will be
      analysed in batch once all samples are collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One group receives Vitamin C, the other group received placebo.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmia</measure>
    <time_frame>First 5 days postoperatively</time_frame>
    <description>Incidence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hours of endotracheal ventilation</measure>
    <time_frame>from arrival at ICU after surgery until the time of discharge from ICU. average 48 hours.</time_frame>
    <description>number of hours of endotracheal ventilation after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay at ICU</measure>
    <time_frame>from time of arrival at ICU after surgery until the time of discharge from ICU. upto 14 days. average 48 hours.</time_frame>
    <description>number of hours in the Intensive Care Unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the hospital</measure>
    <time_frame>from time of arrival at ICU after surgery until the time of hospital discharge. upto 120 days.</time_frame>
    <description>number of hours in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of postoperative medication</measure>
    <time_frame>from time of arrival at ICU after surgery until the time of hospital discharge. upto 120 days</time_frame>
    <description>Total cost (â‚¬) of postoperative medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subclinical kidney damage</measure>
    <time_frame>after induction of anesthesia and two hours after CPB</time_frame>
    <description>change in Value of NGAL between pre-incision and post-CPB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>from time of arrival at ICU until the time of hospital discharge. upto 120 days</time_frame>
    <description>Number of unexpected complications requiring medical interventions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin C 1000mg PO from 5 days before surgery until 10 days after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo as an alternative for Vitamin C tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.</description>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent

          -  eligible for elective cardiac surgery

          -  preoperative sinus rhythm

        Exclusion Criteria:

          -  patients who do not want to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain F Kalmar, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maria Middelares Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain F Kalmar, MD,PhD,MSc</last_name>
    <phone>+32 246 17 00</phone>
    <email>alain.kalmar@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicky Van Der Vekens, DVM,PhD,MSc</last_name>
    <phone>+32 246 17 09</phone>
    <email>nicky.vandervekens@azmmsj.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Stam</last_name>
      <email>kathleen.stam@azmmsj.be</email>
    </contact>
    <investigator>
      <last_name>Jan Heerman, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Algemeen Ziekenhuis Maria Middelares</investigator_affiliation>
    <investigator_full_name>Dr. Alain Kalmar, MD, PhD</investigator_full_name>
    <investigator_title>Staff Anesthesist</investigator_title>
  </responsible_party>
  <keyword>Post-operative atrial fibrillation</keyword>
  <keyword>Ascorbic Acid</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>antioxidant</keyword>
  <keyword>Cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

